Market News AIOpen the app

BofA Securities analyst Alec Stranahan lowered the price target for ProQR Therapeutics from $8 to $7.

OpinionRead the original at moomoo.com
Neutral

BofA kept its Buy rating but cut its price target from $8 to $7. Those mixed analyst views do not report a change in ProQR's business.

PRQR · ProQR Therapeutics

AI read · Neutral

The AI's read

The update changes one analyst's view, not ProQR's reported business results. Keeping a Buy rating points one way, but lowering the target points the other way. The story reports no company news, so it does not change ProQR's business picture.

Get alerts for PRQR

Follow ProQR Therapeutics (PRQR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PRQR
Free on the App Store and Google Play, or on the web.